CO6270328A2 - Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b - Google Patents
Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas bInfo
- Publication number
- CO6270328A2 CO6270328A2 CO10054272A CO10054272A CO6270328A2 CO 6270328 A2 CO6270328 A2 CO 6270328A2 CO 10054272 A CO10054272 A CO 10054272A CO 10054272 A CO10054272 A CO 10054272A CO 6270328 A2 CO6270328 A2 CO 6270328A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- bromo
- fluoro
- cyano
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Abstract
1.- Un compuesto de Formula (I), o una sal farmacéuticamente aceptable del mismo:en la que: Y representa CH o N; Z1-Z2 representa un grupo seleccionado entre C(R6)CH, N=CH y C(R6)N; donde R6 representa hidrogeno, fluoro, cloro, bromo, ciano, metilo, etilo, difluorometilo, trifluorometilo o ciclopropilo; n es 0, 1 o 2; R1 representa alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcoxi C1-4 alquilo C1-4, fluoroalquilo C1-4, aminoalquilo C1-4, hidroxialquilo C1-4, ciano, cianoalquilo C1-4, cicloalquilo C3-5, -(CH2)pNHCOCH3, -(CH2)pNHSO2CH3, -(CH2)pNHCONH2, -(CH2)pNHCONR2R3, -(CH2)pNR2R3, -(CH2)pSO2NH2, -(CH2)pSO2NR2R3, -(CH2)pCONH2, -(CH2)pCONR2R3 o -(CH2)p-R7; donde p es 0, 1, 2 o 3; R2 representa hidrogeno o alquilo C1-3; R3 representa alquilo C1-3; y R7 representa fenilo; R7 representa un anillo heteroarilo monociclico de 5 o 6 miembros que comprende 1, 2 o 3 heteroatomos seleccionados de O, N o S; o R7 representa un anillo heterociclico de 4, 5 o 6 miembros monociclico que comprende 1, 2 o 3 heteroatomos seleccionados de O, N o S; en los que R7 esta opcionalmente sustituido con 1 o 2 sustituyentes seleccionados de alquilo C1-4, trifluorometilo, alcoxi C1-4, fluoro, cloro, bromo, y ciano; R4 representa hidrogeno, fluoro, cloro, bromo, ciano o trifluorometilo; y R5 representa hidrogeno, fluoro, cloro o bromo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97919207P | 2007-10-11 | 2007-10-11 | |
US4786208P | 2008-04-25 | 2008-04-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6270328A2 true CO6270328A2 (es) | 2011-04-20 |
Family
ID=40251789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO10054272A CO6270328A2 (es) | 2007-10-11 | 2010-05-06 | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b |
Country Status (38)
Country | Link |
---|---|
US (8) | US8101623B2 (es) |
EP (1) | EP2201012B1 (es) |
JP (2) | JP4705695B2 (es) |
KR (1) | KR101494734B1 (es) |
CN (1) | CN101861321B (es) |
AR (1) | AR068846A1 (es) |
AU (1) | AU2008309383B2 (es) |
BR (1) | BRPI0818533B8 (es) |
CA (1) | CA2701057C (es) |
CL (1) | CL2008003023A1 (es) |
CO (1) | CO6270328A2 (es) |
CR (1) | CR11359A (es) |
CU (1) | CU23886B1 (es) |
CY (1) | CY1116929T1 (es) |
DK (1) | DK2201012T3 (es) |
DO (1) | DOP2010000103A (es) |
EA (1) | EA018512B1 (es) |
ES (1) | ES2522365T3 (es) |
GT (1) | GT201000082A (es) |
HK (1) | HK1143154A1 (es) |
HN (1) | HN2010000653A (es) |
HR (1) | HRP20140807T1 (es) |
IL (1) | IL204721A (es) |
ME (1) | ME01999B (es) |
MX (1) | MX2010003927A (es) |
MY (1) | MY150059A (es) |
NI (1) | NI201000050A (es) |
NZ (1) | NZ585261A (es) |
PE (2) | PE20090964A1 (es) |
PL (1) | PL2201012T3 (es) |
PT (1) | PT2201012E (es) |
RS (1) | RS53552B1 (es) |
SA (1) | SA08290625B1 (es) |
SI (1) | SI2201012T1 (es) |
TW (1) | TWI453021B (es) |
UY (1) | UY31384A1 (es) |
WO (1) | WO2009047563A1 (es) |
ZA (1) | ZA201002318B (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
JP5339291B2 (ja) | 2006-08-10 | 2013-11-13 | オンコセラピー・サイエンス株式会社 | 乳癌に関連する遺伝子およびポリペプチド |
CN101861321B (zh) | 2007-10-11 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
WO2011002772A1 (en) * | 2009-06-29 | 2011-01-06 | Oncotherapy Science, Inc. | Imidazopyridine derivatives and pbk inhibitors containing the same |
GB201020161D0 (en) | 2010-11-26 | 2011-01-12 | Almac Discovery Ltd | Pharmaceutical compounds |
EP2651417B1 (en) | 2010-12-16 | 2016-11-30 | Calchan Limited | Ask1 inhibiting pyrrolopyrimidine derivatives |
BR112013017722A2 (pt) | 2011-01-11 | 2016-07-12 | Glaxosmithkline Llc | combinação |
US9402847B2 (en) * | 2011-04-01 | 2016-08-02 | Astrazeneca Ab | Combinations comprising (S)-4-amino-N-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide |
CA2856646C (en) | 2011-11-30 | 2020-01-14 | Astrazeneca Ab | Combination treatment of cancer |
AU2013205648B2 (en) * | 2011-11-30 | 2015-02-05 | Astrazeneca Ab | Combination treatment |
AU2013204533B2 (en) | 2012-04-17 | 2017-02-02 | Astrazeneca Ab | Crystalline forms |
MX361136B (es) | 2013-01-23 | 2018-11-28 | Astrazeneca Ab | Compuestos quimicos. |
EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
JP6295578B2 (ja) * | 2013-09-30 | 2018-03-20 | 凸版印刷株式会社 | 反応容器、核酸解析装置、および核酸解析方法 |
US20160228456A1 (en) * | 2013-10-01 | 2016-08-11 | Novartis Ag | Combination |
EP3392244A1 (en) | 2014-02-13 | 2018-10-24 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
AU2015217073B2 (en) | 2014-02-13 | 2019-08-22 | Incyte Holdings Corporation | Cyclopropylamines as LSD1 inhibitors |
US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
HUE045725T2 (hu) | 2014-02-13 | 2020-01-28 | Incyte Corp | Ciklopropilaminok mint LSD1 inhibitorok |
KR102518994B1 (ko) * | 2014-05-28 | 2023-04-05 | 아스트라제네카 아베 | Azd5363의 제조 방법 및 그에 사용되는 신규 중간체 |
WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
WO2016007736A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyrazines as lsd1 inhibitors |
TWI714567B (zh) | 2015-04-03 | 2021-01-01 | 美商英塞特公司 | 作為lsd1抑制劑之雜環化合物 |
MY189367A (en) * | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
TW201726140A (zh) * | 2015-09-17 | 2017-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之新型生物標記及方法 |
EP3445339B1 (en) | 2016-04-22 | 2023-08-23 | Incyte Corporation | Formulations of an lsd1 inhibitor |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
JP2023501317A (ja) | 2019-11-04 | 2023-01-18 | アストラゼネカ・アクチエボラーグ | B細胞悪性腫瘍を処置するためのアカラブルチニブとカピバセルチブとの治療的組み合わせ |
US20240051964A1 (en) * | 2021-01-04 | 2024-02-15 | Teva Pharmaceuticals International Gmbh | Solid state forms of capivasertib and process for preparation thereof |
WO2023187037A1 (en) | 2022-03-31 | 2023-10-05 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
CN114601836B (zh) * | 2022-04-12 | 2022-12-06 | 四川大学华西医院 | 一种akt抑制剂在制备治疗乳腺癌的药物中的应用 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE637271A (es) | 1963-04-04 | 1900-01-01 | ||
GB9312853D0 (en) | 1993-06-22 | 1993-08-04 | Euro Celtique Sa | Chemical compounds |
GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
TR199801530T2 (xx) | 1996-02-13 | 1998-11-23 | Zeneca Limited | VEGF �nhibit�rleri olarak kinazolin t�revleri. |
JP4464466B2 (ja) | 1996-03-05 | 2010-05-19 | アストラゼネカ・ユーケイ・リミテッド | 4―アニリノキナゾリン誘導体 |
AU715202B2 (en) | 1996-04-03 | 2000-01-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
ATE359515T1 (de) | 1997-02-12 | 2007-05-15 | Electrophoretics Ltd | Proteinmarker für lungenkrebs und deren verwendung |
US6432947B1 (en) | 1997-02-19 | 2002-08-13 | Berlex Laboratories, Inc. | N-heterocyclic derivatives as NOS inhibitors |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
ATE296825T1 (de) | 1997-08-05 | 2005-06-15 | Pfizer Prod Inc | 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten |
US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
SK18542000A3 (sk) | 1998-06-04 | 2001-12-03 | Abbott Laboratories | Protizápalové zlúčeniny inhibujúce bunkovú adhéziu |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
CZ306810B6 (cs) | 1999-02-10 | 2017-07-19 | Astrazeneca Ab | Použití chinazolinového derivátu jako inhibitoru angiogeneze |
EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
UA72946C2 (uk) | 1999-11-05 | 2005-05-16 | Астразенека Аб | Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf) |
US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
CA2399358C (en) | 2000-02-15 | 2006-03-21 | Sugen, Inc. | Pyrrole substituted 2-indolinone protein kinase inhibitors |
WO2001092224A1 (en) | 2000-05-31 | 2001-12-06 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
EE200200711A (et) | 2000-06-26 | 2004-06-15 | Pfizer Products Inc. | Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid |
IL153484A0 (en) | 2000-07-07 | 2003-07-06 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors |
BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
DE60114852T2 (de) | 2000-08-31 | 2006-07-27 | F. Hoffmann-La Roche Ag | Chinazolin-derivate als alpha-1 adrenerge antagonisten |
US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
PL363245A1 (en) | 2000-12-01 | 2004-11-15 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine a1 |
US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
EP1390353A1 (en) * | 2001-04-27 | 2004-02-25 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
MXPA04006614A (es) | 2002-01-07 | 2004-10-04 | Eisai Co Ltd | Deazapurinas y usos de las mismas. |
TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
EP1522314B1 (en) | 2002-06-26 | 2014-03-05 | Ono Pharmaceutical Co., Ltd. | Remedies for diseases caused by vascular contraction or dilation |
US20040138238A1 (en) | 2002-08-08 | 2004-07-15 | Dhanoa Dale S. | Substituted aminopyrimidine compounds as neurokinin antagonists |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
JP2006503826A (ja) | 2002-09-06 | 2006-02-02 | スミスクライン・ビーチャム・コーポレイション | ピロロ[2,3−d]ピリミジン−4−イルおよびプリン−6−イル尿素化合物 |
EP1567495A4 (en) | 2002-11-08 | 2007-10-31 | Harvard College | SMALL, WITH TECHNETIUM-99M AND RHENIUM-MARKED MEDIUM AND METHOD OF ILLUMINATING WOVEN FABRICS, ORGANS AND TUMORS |
WO2004050656A1 (ja) | 2002-12-04 | 2004-06-17 | Eisai Co., Ltd. | 1,3−ジヒドロ−イミダゾール縮合環化合物 |
EP1444982A1 (de) | 2003-02-06 | 2004-08-11 | Merckle Gmbh | Verwendung von Purinderivaten als selektive Kinase-Inhibitoren |
MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
CA2507893A1 (en) | 2003-04-21 | 2004-11-04 | Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky | (purin-6-yl) amino acid and production method thereof |
FR2856685B1 (fr) | 2003-06-25 | 2005-09-23 | Merck Sante Sas | Derives de thiazolylpiperidine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
WO2005020921A2 (en) | 2003-08-29 | 2005-03-10 | Exelixis, Inc. | C-kit modulators and methods of use |
WO2005044181A2 (en) | 2003-09-09 | 2005-05-19 | Temple University-Of The Commonwealth System Of Higher Education | Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
KR101223914B1 (ko) | 2003-11-21 | 2013-01-18 | 어레이 바이오파마 인크. | Akt 단백질 키나제 억제제 |
EP2308562B1 (en) | 2003-12-25 | 2015-02-25 | Ono Pharmaceutical Co., Ltd. | Azetidine ring compounds and drugs comprising the same |
BRPI0508230A (pt) * | 2004-03-30 | 2007-07-17 | Chiron Corp | derivados de tiofeno substituìdo como agentes anti-cáncer |
WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
ATE543821T1 (de) * | 2004-12-28 | 2012-02-15 | Exelixis Inc | Ä1h-pyrazoloä3,4-düpyrimidin-4-ylü-piperidin- oder piperazinverbindungen als serin-threonin- kinasemodulatoren (p70s6k, atk1 und atk2) zur behandlung von immunologischen, entzündlichen und proliferativen erkrankungen |
FR2880626B1 (fr) | 2005-01-13 | 2008-04-18 | Aventis Pharma Sa | Derives de la purine, compositions les contenant et utilisation |
FR2880540B1 (fr) | 2005-01-13 | 2008-07-11 | Aventis Pharma Sa | Utilisation de derives de la purine comme inhibiteurs de la proteine hsp90 |
WO2006091450A1 (en) | 2005-02-18 | 2006-08-31 | Lexicon Genetics Incorporated | 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds |
US20060281768A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Thienopyrimidine and thienopyridine kinase modulators |
KR20080026654A (ko) | 2005-07-14 | 2008-03-25 | 아스텔라스세이야쿠 가부시키가이샤 | 헤테로시클릭 야누스 키나제 3 억제제 |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
EP1979353A2 (en) | 2006-01-19 | 2008-10-15 | OSI Pharmaceuticals, Inc. | Fused heterobicyclic kinase inhibitors |
US20090124610A1 (en) | 2006-04-25 | 2009-05-14 | Gordon Saxty | Pharmaceutical compounds |
US20090082370A1 (en) | 2006-04-25 | 2009-03-26 | Neil Thomas Thompson | Pharmaceutical Combinations of PK Inhibitors and Other Active Agents |
WO2007125325A1 (en) | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Pharmaceutical compounds |
JP5606734B2 (ja) | 2006-04-25 | 2014-10-15 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
EP2016077A2 (en) | 2006-04-25 | 2009-01-21 | Astex Therapeutics Limited | Pharmaceutical compounds |
AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
EP2815750A1 (en) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
AR064416A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas. |
CN101861321B (zh) | 2007-10-11 | 2013-02-06 | 阿斯利康(瑞典)有限公司 | 作为蛋白激酶b抑制剂的吡咯并[2,3-d]嘧啶衍生物 |
-
2008
- 2008-10-09 CN CN200880116651XA patent/CN101861321B/zh active Active
- 2008-10-09 JP JP2010528485A patent/JP4705695B2/ja active Active
- 2008-10-09 KR KR1020107010107A patent/KR101494734B1/ko active IP Right Grant
- 2008-10-09 ES ES08806741.8T patent/ES2522365T3/es active Active
- 2008-10-09 TW TW097139021A patent/TWI453021B/zh active
- 2008-10-09 RS RS20140457A patent/RS53552B1/en unknown
- 2008-10-09 ME MEP-2014-102A patent/ME01999B/me unknown
- 2008-10-09 MY MYPI2010001617A patent/MY150059A/en unknown
- 2008-10-09 BR BRPI0818533A patent/BRPI0818533B8/pt active IP Right Grant
- 2008-10-09 SI SI200831281T patent/SI2201012T1/sl unknown
- 2008-10-09 PT PT88067418T patent/PT2201012E/pt unknown
- 2008-10-09 DK DK08806741.8T patent/DK2201012T3/da active
- 2008-10-09 PL PL08806741T patent/PL2201012T3/pl unknown
- 2008-10-09 WO PCT/GB2008/050925 patent/WO2009047563A1/en active Application Filing
- 2008-10-09 MX MX2010003927A patent/MX2010003927A/es active IP Right Grant
- 2008-10-09 AU AU2008309383A patent/AU2008309383B2/en active Active
- 2008-10-09 CA CA2701057A patent/CA2701057C/en active Active
- 2008-10-09 EA EA201000552A patent/EA018512B1/ru not_active IP Right Cessation
- 2008-10-09 UY UY31384A patent/UY31384A1/es not_active Application Discontinuation
- 2008-10-09 NZ NZ585261A patent/NZ585261A/en unknown
- 2008-10-09 EP EP08806741.8A patent/EP2201012B1/en active Active
- 2008-10-10 PE PE2008001748A patent/PE20090964A1/es active IP Right Grant
- 2008-10-10 US US12/249,477 patent/US8101623B2/en active Active
- 2008-10-10 CL CL2008003023A patent/CL2008003023A1/es unknown
- 2008-10-10 AR ARP080104450A patent/AR068846A1/es active IP Right Grant
- 2008-10-10 PE PE2012002041A patent/PE20130152A1/es not_active Application Discontinuation
- 2008-10-11 SA SA8290625A patent/SA08290625B1/ar unknown
-
2010
- 2010-03-25 IL IL204721A patent/IL204721A/en active IP Right Grant
- 2010-03-31 ZA ZA2010/02318A patent/ZA201002318B/en unknown
- 2010-04-09 CR CR11359A patent/CR11359A/es unknown
- 2010-04-09 DO DO2010000103A patent/DOP2010000103A/es unknown
- 2010-04-09 CU CU20100062A patent/CU23886B1/es active IP Right Grant
- 2010-04-09 NI NI201000050A patent/NI201000050A/es unknown
- 2010-04-09 HN HN2010000653A patent/HN2010000653A/es unknown
- 2010-04-09 GT GT201000082A patent/GT201000082A/es unknown
- 2010-05-06 CO CO10054272A patent/CO6270328A2/es active IP Right Grant
- 2010-10-12 HK HK10109649.4A patent/HK1143154A1/xx unknown
-
2011
- 2011-03-09 JP JP2011051117A patent/JP5330430B2/ja active Active
- 2011-12-13 US US13/324,191 patent/US20120190679A1/en not_active Abandoned
-
2014
- 2014-08-26 HR HRP20140807AT patent/HRP20140807T1/hr unknown
- 2014-08-28 CY CY20141100689T patent/CY1116929T1/el unknown
-
2015
- 2015-02-19 US US14/626,303 patent/US9492453B2/en active Active
-
2016
- 2016-11-15 US US15/351,481 patent/US10059714B2/en active Active
-
2018
- 2018-07-06 US US16/028,979 patent/US10654855B2/en active Active
-
2020
- 2020-04-07 US US16/841,820 patent/US11236095B2/en active Active
-
2021
- 2021-12-16 US US17/644,654 patent/US11760760B2/en active Active
-
2023
- 2023-08-04 US US18/365,286 patent/US20240109902A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6270328A2 (es) | Derivados de pirrolo [2,3] pirimidina como inhibidores de proteinas quinasas b | |
ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
AR073688A1 (es) | Agonistas de receptores cb2, derivados de oxazoles y/o triazoles, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor, enfermedades autoinmunes y alergicas, entre otras. | |
ES2485867T3 (es) | Compuestos opioides de carboxamido | |
EA200700758A1 (ru) | Новые производные бис-азаиндолов, их получение и фармацевтическое применение в качестве ингибиторов киназ | |
ES2564782T3 (es) | Compuestos derivados de 1-aril-5-alquil pirazol, procedimientos de fabricación y procedimientos de utilización de los mismos | |
AR056764A1 (es) | Aminopirimidinas utiles como inhibidores de quinasa | |
MEP22008A (en) | Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics | |
ECSP066967A (es) | Derivados de tetrahidroquinolina y un procedimiento para preparar los mismos | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
AR076900A1 (es) | Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc | |
RS53153B (en) | ANTAGONISTS OF HYSTAMINE -3 RECEPTORS | |
PE20120798A1 (es) | Potentes inhibidores de molecula pequena de autofagia | |
AR062937A1 (es) | Compuestos que modulan el receptor cb2 | |
AR060812A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
AR078833A1 (es) | Derivados de heteroarilos que contienen nitrogeno como inhibidores dela cinasa jak3 | |
CO5650244A2 (es) | Derivados de 3-alquil y 3-alquenilazetidina sustituidos | |
CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
AR072900A1 (es) | Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina | |
ES2334565T3 (es) | Agonistas inversos del receptor cb 1. | |
DOP2010000194A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
AR081387A1 (es) | Derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta 2 y como antagonistas muscarinicos m3, composiciones farmaceuticas y uso de los mismos. | |
RS52562B (en) | (3-ARIL-PIPERAZINE-1-IL) DERIVATI 6,7-DIALCOKSIQUINZOLINE, 6,7-DIALCOKSIFTALAZINE I | |
HRP20040429B1 (en) | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |